UK markets close in 8 hours 14 minutes

Almirall, S.A. (0O9B.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
10.34-0.14 (-1.34%)
As of 05:53PM BST. Market open.

Almirall, S.A.

Ronda General Mitre, 151
Barcelona 08022
34 93 291 30 00

Full-time employees1,904

Key executives

NameTitlePayExercisedYear born
Mr. Carlos Gallardo PiquéCEO, President, Member of Management Board & Chairman of the Board50kN/A1972
Mr. Michael McClellanCFO & Member of Management BoardN/AN/A1972
Mr. Eloi Crespo CerveraChief Industrial Operations Officer & Member of Management BoardN/AN/AN/A
Mr. Esteve Conesa PanicotChief People & Culture Officer and Member of Management BoardN/AN/AN/A
Dr. Volker KoscielnyChief Medical Officer & Member of Management BoardN/AN/AN/A
Dr. Karl ZiegelbauerChief Scientific Officer & Member of Management BoardN/AN/AN/A
Mr. Paolo CioniniChief Commercial Officer Europe & International and Member of Management BoardN/AN/AN/A
Ms. Isabel Cristina GomesCompany Vice Secretary,Chief Legal Officer, General Counsel & Member of Management BoardN/AN/AN/A
Ms. Mercedes Diz LopezChief Marketing Officer & Member of Management BoardN/AN/AN/A
Mr. Pablo Divasson del FraileSenior Director of Investor RelationsN/AN/AN/A
Amounts are as of 31 December 2015, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

Corporate governance

Almirall, S.A.’s ISS governance QualityScore as of 1 June 2024 is 2. The pillar scores are Audit: 4; Board: 3; Shareholder rights: 3; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.